November 11, 2010
Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Tampa Tribune
Away from the spotlight of election news coverage, a committee of the U.S. Food and Drug Administration (FDA) held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.
November 7, 2010
John Horton, President, LegitScript
Huffington Post
For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly? That’s one of the thorny questions addressed by the FDA last week in a two-day, open-to-the-public meeting about “biosimilar” drugs — second-generation versions of drugs made from living organisms, or “biologics.”
November 1, 2010
Dr. Donald Palmisano, Former head of the AMA
Times Picayune
The English writer Aldous Huxley once said that humanity has “an absolute and infinite capacity for taking things for granted.” I think about that as I consider the remarkable achievements we’ve made in medicine over the past century from discoveries like penicillin and insulin to the ability to transplant an organ.
October 29, 2010
Dr. Gary Puckrein, President and CEO, National Minority Quality Forum
Opposing Views
Patient safety is a core component of our medical system. In order to assure that physicians are prescribing the best and safest treatments
October 29, 2010
Dr. Gary Puckrein, President and CEO, National Minority Quality Forum
Opposing Views
Patient safety is a core component of our medical system. In order to assure that physicians are prescribing the best and safest treatments
